Randall Bateman

Professor of Neurology, Charles F and Joanne Knight Distinguished Professor of Neurology

    • 12727 Citations
    20062020

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    Our laboratory's focus is on the causes, diagnosis and future treatments of Alzheimer disease. We directly measure the pathophysiology of Alzheimer disease in humans using multiple techniques and also perform in vitro cell culture experiments. Our group uses a wide variety of assays and techniques from the most basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers for Alzheimer's disease. We have several ongoing studies including: 1) In Vivo metabolism of Aß in Alzheimer's Disease: We have pioneered a new technique to measure amyloid-beta metabolism in humans. Ongoing studies in Alzheimer's disease and controls will address the hypothesis that there is a change in amyloid-beta metabolism in people who develop Alzheimer's disease compared to people who do not. 2) Familial Adult Children Study: We are investigating the changes that occur in autosomal dominant Alzheimer disease; including structural changes by MRI, pathological changes by PET-PIB, functional changes by Clinical Dementia Rating and neuropsychometric testing, and pathophysiological changes in CSF biomarkers and CNS protein production and clearance rates. 3) Pharmacodynamic response of proposed disease modifying therapies for Alzheimer disease are tested by directly measuring the production, clearance and steady-state levels of the targeted proteins, including amyloid-beta. These studies quantitate targeted activity of therapeutics and provide evidence that these compounds are effective in humans. 4) CNS derived proteomics and measurements: We are currently investigating multiple other CNS derived proteins and are developing methods to measure hundreds of protein metabolism profiles in humans using highly sensitive nano-flow mass spectrometry and in vivo labeling techniques. Advanced bio-informatics, cutting edge mass spectrometry, and in vivo and in vitro labeling experiments are used for highly quantitative analysis of proteins.

    Areas of Clinical Interest

    Alzheimer's disease, dementia, geriatric neurology, neurodegenerative diseases, mild cognitive impairment, aging, cognitive function

    Fingerprint Dive into the research topics where Randall Bateman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 21 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease

    Dominantly Inherited Alzheimer Network (DIAN) & PREVENT-AD Research Group, 2020, (Accepted/In press) In : Biological Psychiatry.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Another step forward in blood-based diagnostics for Alzheimer’s disease

    Bateman, R. J., Barthélemy, N. R. & Horie, K., Mar 1 2020, In : Nature medicine. 26, 3, p. 314-316 3 p.

    Research output: Contribution to journalComment/debate

    4 Scopus citations

    A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

    the Dominantly Inherited Alzheimer Network, Mar 1 2020, In : Nature medicine. 26, 3, p. 398-407 10 p.

    Research output: Contribution to journalArticle

  • 18 Scopus citations

    Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease

    DIAN Study Group and the PREVENT-AD Research Group, Sep 15 2020, In : Neurology. 95, 11, p. e1554-e1564

    Research output: Contribution to journalArticle

  • Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)

    Dominantly Inherited Alzheimer Network, Jan 1 2020, In : Alzheimer's and Dementia. 16, 1, p. 219-228 10 p.

    Research output: Contribution to journalArticle

    Open Access